OncLive TV

Atish D. Choudhury, MD, PhD, discusses the background of the A-DREAM trial in patients with metastatic hormone-sensitive prostate cancer.

Tanios Bekaii-Saab, MD, FACP, discusses the future of treatment within the gastrointestinal cancers armamentarium.

Robert Dreicer, MD, discusses complexities surrounding biochemical failure post radical prostatectomy in patients with prostate cancer.

Deborah J. Wong, MD, PhD, discusses challenges incorporating checkpoint inhibitors into curative-intent approaches for patients with head and neck squamous cell carcinoma.

Filipa Lynce, MD, discusses the current prognosis of patients diagnosed with inflammatory breast cancer subtypes.

Misty D. Shields, MD, PhD, discusses the FDA approval of tarlatamab for patients with extensive-stage small cell lung cancer.

Jonathan W. Riess, MD, MS, discusses advancements, as well as unmet needs in the management of thymic malignancies.

Rashad Nawfal, MD, discusses radiological tumor burden as an independent prognostic factor for survival in metastatic clear cell renal cell carcinoma.

Dan Pollyea, MD, MS, discusses the mechanism of action for the menin inhibitor revumenib in KMT2A-rearranged relapsed/refractory acute myeloid leukemia.

Sandip P. Patel, MD, discusses significant areas of advancements in the treatment paradigm for non–small cell lung cancer.

akash Desai, MBBS, MPH, discusses unmet needs with the use of chemoimmunotherapy in patients with non–small cell lung cancer.

Natalia Neparidze, MD, discusses clinical implications and future of belantamab mafodotin and elotuzumab in heavily pretreated, relapsed/refractory multiple myeloma.

Triparna Sen, PhD, discusses the importance of identifying actionable or targetable biomarkers for the management of small cell lung cancer.

Solange Peters, MD, PhD, discusses biomarkers that may inform treatment decision-making prior to immunotherapy use in non–small cell lung cancer.

Millie Das, MD, discusses key trials that have advanced treatment for patients who present with non–small cell lung cancer.

Stephen Opat, MBBS, discusses sonrotoclax plus zanubrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

Praful K. Ravi, MB, BChir, MRCP, discusses the use of residual cancer burden to guide intensified neoadjuvant treatment in high-risk prostate cancer.

Nazli Dizman, MD, discusses the impact of CBM588 on gut microbiome composition in patients with renal cell carcinoma who received immune checkpoint inhibitors in the first line.

Erminia Massarelli, MD, PhD, MS, discusses selpercatinib and pralsetinib in treating advanced non-small cell lung cancer.

Karen L. Reckamp, MD, MS, discusses the role of amivantamab in the treatment of advanced non–small cell lung cancer.

Jacob Sands, MD, discusses updates to the role of antibody-drug conjugates in the treatment of patients with small cell lung cancer.

Fred R. Hirsch, MD, PhD, discusses the activity of HER3-directed agents in patients with non–small cell lung cancer harboring NRG1 mutations.

Lori Wirth, MD, discusses the safety selpercatinib in adult or pediatric patients with advanced or metastatic RET fusion–positive thyroid cancer.

Tanios Bekaii-Saab, MD, FACP, discusses next-generation sequencing and the development of RAS-targeted therapies in gastrointestinal cancers.

Moritz Fürstenau, MD, discusses the safety of venetoclax plus obinutuzumab with/without ibrutinib in fit patients with chronic lymphocytic leukemia.

Jun Gong, MD, discusses the benefits and limitations of PARP inhibitor–based regimens in metastatic castration-resistant prostate cancer.

Thierry Facon, MD, discusses clinical implications from the phase 3 IMROZ trial

Alicia Morgans, MD, MPH, discusses key data from the follow-up analysis of the phase 3 ARAMIS trial in nonmetastatic castration-resistant prostate cancer.

Marshall Posner, MD, discusses the mechanism of action of danvatirsen in recurrent and/or metastatic head and neck squamous cell carcinoma.